GTG 2.22% 9.2¢ genetic technologies limited

Pioneering Genomics for Health and Wellness, page-34

  1. 57 Posts.
    lightbulb Created with Sketch. 5
    The Bakersfield CalifornianGeneType Clinicians’ Adoption Growing - Sales up 5-Fold Year on Year https://www.bakersfield.com/ap/news/genetype-clinicians-adoption-growing---sales-up-5-fold-year-on-year/article_ebccdf40-3b03-5dba-86dc-e1a9f8cbe660.html?utm_medium=social&utm_source=twitter&utm_campaign=user-share via @Bakersfieldcali
    MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to share the company’s latest milestones along with our clinical adoption of the Company’s groundbreaking geneType Risk Assessment Tests routinely across 12 states in the United States and nationally in Australia.The geneType team has achieved clinical proof of concept in key markets including general practice, oncology, and gynecology with repeat sales in each of these markets.
 
watchlist Created with Sketch. Add GTG (ASX) to my watchlist
(20min delay)
Last
9.2¢
Change
0.002(2.22%)
Mkt cap ! $12.16M
Open High Low Value Volume
8.7¢ 9.2¢ 8.7¢ $2.809K 31.31K

Buyers (Bids)

No. Vol. Price($)
1 50000 8.8¢
 

Sellers (Offers)

Price($) Vol. No.
9.2¢ 484 1
View Market Depth
Last trade - 15.53pm 21/06/2024 (20 minute delay) ?
GTG (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.